Abstract
Immunotherapy is based on the understanding of a range of regulatory mechanisms that affect the immune system becomes more viable option in the treatment of lung cancer. It is a completely different method of treatment of cancer, which is not focused on the tumor itself, but on the immune system.
Surface antigens present on tumor cells may be an effective and specific therapeutic targets and strategies based on antibodies inhibiting immune checkpoints significantly improves the anti-tumor immune response. In 2015 the FDA approved anti-PD-1 (programmed cell death protein) an antibody nivolumab in second-line treatment of squamous and non-squamous NSCLC (non small cell lung cancer) and pembrolizumab in PD-L1 positive NSCLC.